Dr. Oberg: Biomarkers Will Be a $150bn USD Market by 2027 for MYND to Tap
We’re only a few days into October, but already it’s proving to be an exciting month for MYND Life Sciences (CNSX: MYND) (OTCMKTS: MYNDF) CEO Dr. Lyle Oberg has joined us on The Dales Report once again to talk about two pieces of news that might well be revolutionary to the medical world. First, Dr. Oberg discusses the new MYND subsidiary dealing strictly with biomarkers for diagnostics for major depressive disorder, and MYND CSO Wilf Jefferies’ discovery that Alzheimer’s disease may be curable. That’s right, curable.
Here’s some highlights from the interview.
MYND’s stance is that neuroinflammation the root cause of MDD, and protein biomarkers can indicate improvement or worsening
Dr. Oberg has visited with us before to discuss that major depressive disorder (MDD) might in fact become easy to diagnose. Contingent on this is the understanding that neuroinflammation is a key player in MDD.
Previously, the DSMV has had to use a cluster of symptoms to diagnose depression in an individual. New research has shown fairly conclusively that there is a protein marker in patients with neuro-inflammation that can be used to not only diagnose depression, but also monitor course of treatment.
Dr. Oberg suggests that once a baseline is established in the patient using MYND’s testing, when the amount of biomarkers decreases, the patient’s depression is worsening; when the biomarker levels rise, one can assume they’re getting better.
New MYND subsidiary will deal with biomarkers and diagnostics only
With that in mind, MYND decided to form a wholly-owned subsidiary to create proprietary tests for biomarkers called MYND Diagnostics Ltd. Dr. Oberg hopes that this biomarker test will become a new gold standard, as it is a vast improvement over current diagnostic techniques.
Not only would MYND’s testing kits for biomarkers be able to diagnose MDD in individuals initially, further testing using the biomarker would help monitor the progression of the disease and success of treatment.
To be able to identify when people are getting worse or better before they recognize changes in their cognition will help facilitate treatment and medication levels. It would also allow more rapid changes to unsuccessful courses of treatment than current.
MYND CSO Dr Wilf Jefferies co-authored a research paper published by The Lancet regarding treatment options for Alzheimer’s
Alzheimer’s disease may finally be on its way towards real treatment. For decades, it has been a progressive disease that can be slowed but not halted.
Dr. Jefferies successfully treated mice with Alzheimer’s plaques with a anti-angiogenic cancer drug. In short, the cancer drug successfully killed blood supply to the plaques, causing them to diminish and go away. If Dr. Jefferies’ research is transferrable to humans, which Dr. Oberg feels that it may be, not only might there be a way to treat Alzheimer’s but actually cure it.
Dr. Oberg has high hopes that psilocybin, which MYND is using to treat MDD, may also prove to be successful in such human patient treatment of Alzheimer’s disease. Not only does psilocybin successfully cross the blood-brain barrier, allowing it to be a neuro anti-inflammatory, it also has anti-angiogenic properties.